A study to find how safe different doses of LFD-200 are and how it works in both healthy people and people with moderate to severe rheumatoid arthritis

2025-523409-13-00 Protocol LFD200A11 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 3 sites · Protocol LFD200A11

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 176
Countries 1
Sites 3

Moderate to Severe Rheumatoid Arthritis

Key facts

Sponsor
Lifordi Immunotherapeutics Inc.
Participant type
Healthy volunteers, Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Decision date (initial)
2026-01-30
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Moderate to Severe Rheumatoid Arthritis

VersionLevelCodeTermSystem organ class
23.1 PT 10039073 Rheumatoid arthritis 100000004859

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Lifordi Immunotherapeutics Inc.

Sponsor organisation
Lifordi Immunotherapeutics Inc.
Address
1 Van De Graaff Drive Suite 400
City
Burlington
Postcode
01803-5176
Country
United States

Scientific contact point

Organisation
Lifordi Immunotherapeutics Inc.
Contact name
Chief Medical Officer

Public contact point

Organisation
Lifordi Immunotherapeutics Inc.
Contact name
Chief Medical Officer

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Poland Authorised, recruitment pending 40 3
Rest of world
Georgia, Moldova, Republic of, Ukraine, Australia
136

Investigational sites

Poland

3 sites · Authorised, recruitment pending
Medicover Integrated Clinical Services Sp. z o.o.
MICS Centrum Medyczne Toruń, Ul. Stefana Batorego 18-22, 87-100, Torun
Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
Centrum Wsparcia Badań Klinicznych, Ul. Spartanska 1, 02-637, Warsaw
Klinika Reuma Park Sp. z o.o. S.K.
Centrum Medyczne Reuma Park, Aleja Wilanowska 333, 02-665, Warsaw

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-09-23 Poland Acceptable
2026-01-26
2026-01-30